Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B

Novartis130 enrolled

Overview

This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

130

Conditions

Hepatitis B

Interventions

telbivudineDRUG

valtorcitabineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical history compatible with compensated chronic hepatitis B Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Patient is pregnant or breastfeeding * Patient is co-infected with hepatitis C virus, hepatitis D virus or HIV * Patient has previously received lamivudine, adefovir dipivoxil or an investigational anti-hepatitis B virus (HBV) nucleoside or nucleotide at anytime. Other protocol-defined exclusion criteria may apply.

Locations (3)

Unnamed facility

Pokfulam, Hong Kong

Unnamed facility

Auckland, New Zealand

Unnamed facility

Singapore, Singapore

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.